Ventricular dysfunction clinical research in infants, children and adolescents

Progress in Pediatric Cardiology

Volumn 12, Issue 1, 2000, Pages 1-28

  Lipshultz, Steven E ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Cardiomyopathy; Clinical trials; Congestive heart failure; Pediatrics; Ventricular function

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM SENSITIZER; CARDIOVASCULAR AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GROWTH HORMONE; INOTROPIC AGENT; VASODILATOR AGENT;

ADOLESCENT; ADULTHOOD; ANIMAL MODEL; CARDIOMYOPATHY; CHILD; CHILDHOOD; CLINICAL RESEARCH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE COURSE; ENERGY METABOLISM; GENE THERAPY; HEART DEVELOPMENT; HEART VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HUMAN; INFANT; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; REVIEW;

EID: 0033658979     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1058-9813(00)00076-X     Document Type: Editorial

References (124)

1. Research in children: ethical and scientific aspects
2. Major advances in pediatric cardiology in the 20th century: I. Diagnostics
3. The end of the clinical anecdote
4. Cardiovascular manifestations of human immunodeficiency infection in infants and children
5. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer
6. Late cardiac effects of doxorubicin in childhood acute lymphoblastic leukemia
7. Abnormalities of cardiac structure and function in HIV-infected children treated with zidovudine
8. Cardiac morbidity and related mortality in children with symptomatic HIV infection
9. Cardiovascular abnormalities in long-term survivors of childhood cancer
10. Monitoring for anthracycline cardiotoxicity
11. Limitations of fractional shortening as an index of contractility in HIV-infected children
12. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer
13. Immunoglobulins and cardiac structure and function in HIV-infected children
14. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the pediatric oncology group experience
15. Clinical approach to genetic cardiomyopathy in children
16. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children
17. 2 HIV multicenter study
18. The relation between cumulative anthracycline dose and late cardiotoxicity in survivors of childhood leukemia
19. Nutritional status and cardiac mass and function in children infected with the human immunodeficience virus
20. Predictive value of cardiac troponin T in pediatrc patients at risk for myocardial injury
21. Left ventricular function in infants and children infected with the human immunodeficiency virus
22. Epidemiology of anthracycline cardiotoxicity in children and adults
23. 2 HIV multicenter study
24. 2 HIV multicenter study
25. Anthracycline induced cardiotoxicity
26. Cardiac troponin T: elevated serum levels and loss from cardiac myocytes in doxorubicin toxicity
27. New developments in the biochemical assessment of myocardial injury in children: troponin T and I as highly sensitive and specific markers of myocardial injury
28. Late cardiotoxicity following anthracycline therapy for childhood cancer
29. Risk factors for early anthracycline cardiotoxicity in children: the pediatric oncology group experience
30. Cardiovascular disease in long-term survivors of pediatric Hodgkin's disease
31. The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease
32. Alterations in cardiac and pulmonary function in pediatric rapid human immunodeficiency virus type 1 disease progressors'
33. Genetics of neonatal cardiomyopathy
34. Dilated cardiomyopathy in HIV-infected patients
35. Correlation between serum levels of cardiac troponin-T and the severity of chronic cardiomyopathy induced by doxorubicin
36. Non-invasive assessment of rejection in pediatric heart transplant patients: serologic and echocardiographic prediction of biopsy proven myocardial rejection
37. Cardiac toxicity of intravenous terbutaline for the treatment of severe asthma in children: a prospective assessment
38. 2 HIV multicenter study
39. Absence of cardiac toxicity of zidovudine in infants
40. Pediatric evidence-based medicine: past, present, and future
41. A comparison of laboratory and epidemiologic approaches to pediatric research
42. A comparison of observational studies and randomized controlled trials
43. Randomized, controlled trials, observational studies and the hierarchy of research designs
44. Randomized trials or observational tribulations?
45. Teaching pediatric cardiology
46. Issues related to subspecialty education: weasel words in action
47. Design and redesign of the heart
48. Cardiovascular health and disease in children: current status
49. Report of the task force on children and youth
50. Pediatric cardiology in the 1990s
51. Design and implementation of the north american pediatric cardiomyopathy registry
52. NHLBI genomics initiatives. Looking beyond the human genome project
53. Systemic gene therapy for cardiovascular disease
54. From bench to bedside: the future is now
55. Clinical trials in childhood cancers
56. Off-label uses of drugs in children
57. Is pediatric labeling really necessary?
58. Academy encourages clinical trials for pediatric cancer drugs
59. Pediatricians should weigh drug trial risks
60. Angiotensin converting inhibitor therapy for ventricular dysfunction in infants, children and adolescents: a review
61. Growth hormone therapy for LV dysfunction: a 10-year experience
62. Pediatric dilated cardiomyopathy: prognosis in a developing nation is comparable to developed nations
63. Specific mitochondrial DNA deletions in idiopathic dilated cardiomyopathy
64. Mitochondrial function in children with idiopathic dilated cardiomyopathy
65. Life-threatening reactions to trimethaprim-sulfamethoxazole in children with HIV infection
66. Cardiovascular complications of pharmacotherapeutic agents (excluding the antiretrovirals) in pediatric HIV infection
67. Retaining and tracking cohort study members
68. Nursing, quality of life, and social issues in HIV-infected patients
69. Cardiovascular manifestations of pediatric HIV infection
70. 2 HIV) infection study: design and methods
71. Coordinating the large multicentered HIV research project
72. Recognizing nurses' contributions to the clinical research process
73. The use of serum cardiac troponin-T to detect myocardial damage during doxorubicin therapy
74. The predictive value of serum cardiac troponin T in children with myocardial damage
75. Cardiac troponin T: elevated serum levels and loss from cardiac myocytes in doxorubicin toxicity
76. Elevated serum cardiac troponin-T as a marker for active cardiac injury during therapy for childhood acute lymphoblastic leukemia
77. Cardiac troponin T (cTnT) as a biomarker for monitoring chronic doxorubicin (dxr) cardiomyopathy
78. Determination of serum cardiac troponin-T as a biomarker of anthracycline cardiotoxicity
79. Diagnosis, surveillance and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of the polymerase chain reaction
80. Tracheal aspirate as a substrate for PCR detection of viral genome in childhood pheumonia and myocarditis
81. Adenovirus infection predicts graft failure after pediatric lung transplantation
82. Clinically unsuspected myocardial injury in children
83. Elevations of serum troponin T and I levels and cardiac abnormalities in children with chronic renal failure
84. Cardiovascular abnormalities in children with chronic renal failure
85. The use of echocardiography and Holter monitoring in the assessment of anthracycline-treated patients
86. Radiation effects on the heart
87. 2 study
88. Cardiovascular abnormalities in infants prenatally exposed to cocaine
89. Arrhythmias in children prenatally exposed to cocaine
90. Report of the National Heart, Lung, and Blood Institute special emphasis panel on Heart Failure Research
91. Etiology and family history of pediatric cardiomyopathy: the early pediatric cardiomyopathy registry (PCMR) experience
92. The incidence of pediatric cardiomyopathy in the NHLBI pediatric cardiomyopathy registry
93. Is enalapril beneficial in doxorubicin-treated long-term survivors of childhood cancer?
94. Chronic progressive LV systolic dysfunction and afterload excess years after doxorubicin therapy for childhood acute lymphoblastic leukemia
95. Effects of the ace inhibitor, enalapril, in children age 6-16 with hypertension
96. Multicenter study of enalapril pharmacokinetics in hypertensive children and infants
97. 48 hour continuous doxorubicin infusion is not cardioprotective in children assessed 18 months later
98. 2 study
99. The American academy of child cardiology
100. Current status of the epidemiology of heart failure
101. The 'inclusion benefit' in clinical trials
102. The national impact of clinical cooperative group trials for pediatric cancer
103. Fifty years of studies of the biology and therapy of childhood leukemia
104. Pediatric patients benefit from inclusion in clinical trials
105. Clinical research saves money: reflections on high-dose therapy of breast cancer
106. Cost of care for patients in cancer clinical trials
107. High-quality clinical databases: breaking down barriers
108. Pediatricians attitudes, beliefs, and practices regarding clinical practice guidelines: a national survey
109. Practice guidelines developed by specialty societies: the need for a critical appraisal
110. Development of practice guidelines
111. Potential benefits, limitations, and harms of clinical guidelines
112. Use of critical pathways to improve the care of patients with acute myocardial infarction
113. Identification of human immunodeficiency virus-1 RNA and DNA in the heart of a child with cardiovascular abnormalities and congenital acquired immune deficiency syndrome